Compare · DGX vs LH
DGX vs LH
Side-by-side comparison of Quest Diagnostics Incorporated (DGX) and Labcorp Holdings Inc. (LH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DGX and LH operate in Medical Specialities (Health Care), so they compete in similar markets.
- DGX is the larger of the two at $21.44B, about the same size as LH ($21.23B).
- Over the past year, DGX is up 11.6% and LH is up 3.3% - DGX leads by 8.2 points.
- DGX has been more active in the news (13 items in the past 4 weeks vs 9 for LH).
- Both have 25 recent analyst ratings on file.
- Company
- Quest Diagnostics Incorporated
- Labcorp Holdings Inc.
- Price
- $193.72+0.32%
- $258.91+0.48%
- Market cap
- $21.44B
- $21.23B
- 1M return
- +1.11%
- +2.33%
- 1Y return
- +11.56%
- +3.32%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NYSE
- IPO
- News (4w)
- 13
- 9
- Recent ratings
- 25
- 25
Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Labcorp Holdings Inc.
Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty Testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. In addition, it provides online and mobile applications to enable patients to check test results; patient self-service apps; and online applications for managed care organizations. Further, it offers end-to-end drug development, medical device, and diagnostic development solutions from early-stage research to clinical development and commercial market access. The company primarily serves managed care organizations, biopharmaceutical companies, physicians and other healthcare providers, hospitals and health systems, governmental agencies, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, and independent clinical laboratories. The company was founded in 1971 and is headquartered in Burlington, North Carolina.
Latest DGX
- CEO and President Davis J. E. sold $1,941,400 worth of shares (10,000 units at $194.14) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 132,423 units (SEC Form 4)
- Director Carter Robert B was granted 1,142 shares, increasing direct ownership by 42% to 3,853 units (SEC Form 4)
- Director Gregg Vicky B was granted 1,142 shares, increasing direct ownership by 7% to 18,314 units (SEC Form 4)
- Director Main Timothy L was granted 1,142 shares, increasing direct ownership by 4% to 27,439 units (SEC Form 4)
- Director Diaz Luis was granted 1,142 shares, increasing direct ownership by 28% to 5,196 units (SEC Form 4)
- Director Wentworth Timothy C was granted 1,142 shares, increasing direct ownership by 529% to 1,358 units (SEC Form 4)
- Director Doi Tracey was granted 1,142 shares, increasing direct ownership by 17% to 7,748 units (SEC Form 4)
- Director Ring Timothy M was granted 1,142 shares, increasing direct ownership by 4% to 31,140 units (SEC Form 4)
- Director Lassiter Wright Iii was granted 1,142 shares, increasing direct ownership by 12% to 10,317 units (SEC Form 4)
- Director Morrison Denise M was granted 1,142 shares, increasing direct ownership by 11% to 11,929 units (SEC Form 4)
Latest LH
- Labcorp Supports Multi-Institution Trial to Expand Genetic Testing in Colorectal Cancer
- Labcorp Launches Expanded DPYD Test to Identify Cancer Patients at Risk for Severe Chemotherapy Side Effects
- Labcorp Holdings Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Labcorp to Present at the Jefferies Global Healthcare Conference
- Labcorp Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form SD filed by Labcorp Holdings Inc.
- Labcorp Launches MyLabcorp™, a New AI-Powered Mobile App Designed to Help Consumers Understand Lab Results and Track Health Trends Over Time
- President & CEO Schechter Adam H sold $1,502,314 worth of shares (5,903 units at $254.50) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 107,234 units (SEC Form 4)
- Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems
- SEC Form 144 filed by Labcorp Holdings Inc.